Replies to post #186869 on Biotech Values

[jq1234]

Under the radar:

There are so few pure gene therapy companies out there, how and why is AGTC under the radar? It seems to me AAVL, ONCE just had better clinic data to reflect their larger market caps. I wouldn't argue if you say they might be somewhat over valued currently, that doesn't mean the likes of AGTC, CLDN, QURE are undervalued.

There was similar argument about Cellectis valuation relative to KITE and JUNO. To me, relative valuation is appropriate because of higher risk nature of allogeneic CAR-T without any clinic data. Again, I wouldn't argue with those who say KITE, JUNO are over valued currently, that doesn't mean the RELATIVE valuation is wrong.

This doesn't mean you can't have good returns from those with lower market caps, you certainly can, but it comes with the risk you take from future clinical data.